Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.87
- Piotroski Score 2.00
- Grade Buy
- Symbol (PLX)
- Company Protalix BioTherapeutics, Inc.
- Price $1.39
- Changes Percentage (12.1%)
- Change $0.15
- Day Low $1.26
- Day High $1.39
- Year High $1.90
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.08
- Trailing P/E Ratio 14
- Forward P/E Ratio 14
- P/E Growth 14
- Net Income $8.31 M
Income Statement
Quarterly
Annual
Latest News of PLX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Q3 2024 MPLX LP Earnings Call
MPLX reported strong financial results, with record EBITDA and distributable cash flow growth. The focus is on organic growth and strategic investments, aiming for a 12.5% distribution increase....
By Yahoo! Finance | 1 week ago -
Stocks Showing Improved Relative Strength: MPLX
Learn how to scale out of losing stocks using three signals, including IBD's proprietary rating system that tracks price movement from 1 to 99. Discover the importance of an 80+ RS Rating for successf...
By Investor's Business Daily | 1 week ago -
MPLX LP (MPLX) Q3 2024 Earnings Call Highlights: Record EBITDA and Strategic Growth Initiatives
Phillips' Southern California refinery closure may affect MPLX LP's logistics assets. MPLX increased its distribution by 12.5% due to strong cash flows and growth projects. Focus on mid-single-digit g...
By Yahoo! Finance | 1 week ago
